17 results on '"Westervelt, Peter"'
Search Results
2. Ruxolitinib for steroid‐refractory acute graft‐versus‐host disease.
- Author
-
Toama, Wael, Fiala, Mark, Pusic, Iskra, Westervelt, Peter, Dipersio, John F., and Schroeder, Mark
- Subjects
GRAFT versus host disease ,ACUTE diseases - Abstract
Twenty-four patients (67%) received at least 14 days of treatment and were evaluable for response; the overall response rate (ORR) was 58% (95% CI 38%-78%) with 25% obtaining a complete (CR). In addition, we included patients who received numerous prior treatments for SR-aGVHD, while REACH1 only allowed patients to receive calcineurin inhibitors. Response of 443 patients to steroids as primary therapy for acute graft-versus-host disease: comparison of grading systems. [Extracted from the article]
- Published
- 2020
- Full Text
- View/download PDF
3. Peritransplant Serum Albumin Decline Predicts Subsequent Severe Acute Graft-versus-Host Disease after Mucotoxic Myeloablative Conditioning.
- Author
-
Rashidi, Armin, DiPersio, John F., Westervelt, Peter, Abboud, Camille N., Schroeder, Mark A., Cashen, Amanda F., Pusic, Iskra, and Romee, Rizwan
- Subjects
- *
MYELOSUPPRESSION , *SERUM albumin , *DISEASE risk factors , *GRAFT versus host disease , *HEMATOPOIETIC stem cell transplantation , *ACUTE myeloid leukemia , *MYELODYSPLASTIC syndromes , *PATIENTS - Abstract
Conditioning-related gut toxicity can result in a protein-losing enteropathy manifesting as a decline in serum albumin in the peritransplant period. Inspired by the pathogenesis of acute graft-versus-host disease (aGVHD), we hypothesized that the magnitude of decline in serum albumin from the day of conditioning initiation until its nadir in the first 2 weeks after hematopoietic cell transplantation HCT (DeltaAlb) predicts the risk for subsequent severe aGVHD. We reviewed the medical records of all 88 patients with acute myeloid leukemia or myelodysplastic syndrome who underwent highly mucotoxic myeloablative (busulfan/cyclophosphamide or cyclophosphamide/total body irradiation) allogeneic HCT from a matched related donor (MRD) or matched unrelated donor (MUD) at our institution between January 1, 2012 and January 1, 2015. Severe aGVHD was associated with MUD (47% versus 14% with MRD; P = .001) and DeltaAlb, which was significantly greater among patients who developed versus did not develop severe aGVHD (1.2 ± .5 versus .8 ± .4 g/dL, respectively; P < .001). In multivariate analysis DeltaAlb remained a significant predictor of severe aGVHD (odds ratio, 5.68; 95% CI, 1.65 to 19.64; P = .006; area under the ROC curve, .74; 95% CI, .63 to .86; P < .001). The best cutoff for DeltaAlb to predict severe aGVHD was .9, with a sensitivity, specificity, and overall classification accuracy of 77%, 66%, and 69%, respectively. The model was validated using the bootstrap technique, with no significant change in its performance. These results were not generalizable to a cohort of 30 patients who received less mucotoxic myeloablative or reduced-intensity conditioning. In conclusion, with mucotoxic myeloablative HCT, each .1-g/dL increase in DeltaAlb was associated with an approximately 23% increase in the odds of developing severe aGVHD. As an early biomarker of gut damage, DeltaAlb can be incorporated in composite risk models for aGVHD prediction, with hopes for ultimately allowing for individualized GVHD prophylaxis and potential intervention according to the predicted risk. [ABSTRACT FROM AUTHOR]
- Published
- 2016
- Full Text
- View/download PDF
4. Reduced-Intensity Allogeneic Transplantation Provides High Event-Free and Overall Survival in Patients with Advanced Indolent B Cell Malignancies: CALGB 109901
- Author
-
Shea, Thomas, Johnson, Jeffrey, Westervelt, Peter, Farag, Sherif, McCarty, John, Bashey, Asad, Isola, Luis, Baxter-Lowe, Lee-Anne, Kelly, Michael, Owzar, Kouros, and Linker, Charles
- Subjects
- *
HEMATOPOIETIC stem cells , *STEM cell transplantation , *B cell lymphoma , *CANCER relapse , *CANCER chemotherapy , *GRAFT versus host disease , *PATIENTS - Abstract
Cancer and Leukemia Group B conducted a phase II study to evaluate the safety and efficacy of a reduced-intensity conditioning regimen with allogeneic transplantation to treat patients with recurrent low-grade B cell malignancies. Patients over age 18 with a diagnosis of relapsed, chemotherapy-sensitive disease underwent transplantation with a matched sibling donor, and conditioning with cyclophosphamide (1 g/m2/day × 3) and fludarabine phosphate (25 mg/m2/day × 5). Graft-versus-host prophylaxis included cyclosporine or tacrolimus plus low-dose methotrexate. Forty-four evaluable patients with a median age of 53 and median of 2 prior regimens were accrued. Sixteen patients had follicular non-Hodgkin lymphoma and 28 had histologies including 7 indolent B cell lymphomas, 4 mantle cell, 15 chronic lymphocytic leukemia (CLL), and 2 prolymphocytic leukemia (PLL) patients. The 6-month treatment-related mortality (TRM) was 2.4% and 3-year TRM was 9%. Three-year event-free and overall survival were 0.75 and 0.81 for the follicular patients, 0.59 and 0.71 for the CLL/PLL patients, and 0.55 and 0.64 for the other histologies. The incidence of grade II-IV acute graft-versus-host disease (GVHD) was 29%, and extensive chronic GVHD was 18%. This report demonstrates that allogeneic sibling transplantation with a reduced-intensity conditioning regimen is safe and efficacious for patients with advanced indolent B cell malignancies enrolled on a Cooperative Group study. [ABSTRACT FROM AUTHOR]
- Published
- 2011
- Full Text
- View/download PDF
5. The Predicted Indirectly Recognizable HLA Epitopes (PIRCHE) Score for HLA Class I Graft-versus-Host Disparity Is Associated with Increased Acute Graft-versus-Host Disease in Haploidentical Transplantation with Post-Transplantation Cyclophosphamide.
- Author
-
Rimando, Joseph, Slade, Michael, DiPersio, John F., Westervelt, Peter, Gao, Feng, Liu, Chang, and Romee, Rizwan
- Subjects
- *
GRAFT versus host disease , *ACUTE diseases , *EPITOPES , *CELLULAR recognition , *CELL transplantation , *CYTOTOXIC T cells - Abstract
• PIRCHE scores offer a method of quantifying indirect T cell alloreactivity. • PIRCHE scores offer a broad range of measurement of HLA disparity. • Graft-versus-host PIRCHE scores correlate with acute graft-versus-host disease. • PIRCHE scores may improve donor selection in haploidentical transplantation. The Predicted Indirectly Recognizable HLA Epitopes (PIRCHE) score quantifies the number of PIRCHEs in patient-donor pairs and represents an in silico measure of indirect alloreactivity. This biologic process is defined as T cell recognition of epitopes derived from mismatched, allogeneic HLA peptides that are subsequently presented by shared HLA molecules. Its association with clinical outcome has not been examined in haploidentical hematopoietic cell transplantation (haplo-HCT) with post-transplantation cyclophosphamide (PTCy). We hypothesized that the PIRCHE score (PS) would correlate with indirect alloreactivity and predict graft-versus-host disease (GVHD) risk and the incidence of relapse after haplo-HCT with PTCy. We retrospectively analyzed 148 patients who underwent peripheral blood stem cell T cell-replete haplo-HCT with PTCy at a single center between 2009 and 2016. For each patient-donor pair, the PS was calculated using the PIRCHE online matching tool. PSs were categorized by class and vector. The median class I graft-versus-host (GVH) PS was 11 (range, 0 to 56), and the median class I host-versus-graft (HVG) PS was 10 (range, 0 to 51). Class I GVH PS was associated with increased risk of grade II-IV acute GVHD (adjusted hazard ratio, 1.03 per PS unit increase; 95% confidence interval, 1.01 to 1.05; P =.008) but not of chronic GVHD or relapse. Our data show that use of the PS is a novel strategy for predicting clinical outcome in haplo-HCT; further studies using registry data and prospective cohorts are warranted to validate these findings. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
6. Effect of Antihuman T Lymphocyte Globulin on Immune Recovery after Myeloablative Allogeneic Stem Cell Transplantation with Matched Unrelated Donors: Analysis of Immune Reconstitution in a Double-Blind Randomized Controlled Trial.
- Author
-
Gooptu, Mahasweta, Kim, Haesook.T., Chen, Yi-Bin, Rybka, Witold, Artz, Andrew, Boyer, Michael, Johnston, Laura, McGuirk, Jim, Shea, Thomas C., Jagasia, Madan, Shaughnessy, Paul J., Reynolds, Carol G., Fields, Marie, Alyea, Edwin P., Ho, Vincent. T., Glavin, Frank, Dipersio, John F., Westervelt, Peter, Ritz, Jerome, and Soiffer, Robert J.
- Subjects
- *
STEM cell transplantation , *IMMUNE reconstitution inflammatory syndrome , *CLINICAL trials , *GRAFT versus host disease , *CYTOMETRY - Abstract
Abstract We recently conducted a randomized double-blind study in which we demonstrated that moderate/severe chronic graft-versus-host disease (cGVHD) but not cGVHD-free survival was reduced in patients receiving anti-T lymphocyte globulin (ATLG) versus placebo. In a companion study we performed immunophenotypic analysis to determine the impact of ATLG on immune reconstitution (IR) and to correlate IR with clinical outcomes. The randomized study (n = 254) included patients (aged 18 to 65 years) who underwent myeloablative transplants for acute myeloid leukemia, myelodysplastic syndrome, or acute lymphoblastic leukemia from HLA-matched unrelated donors. Ninety-one patients consented for the companion IR study (ATLG = 44, placebo = 47). Blood samples were collected on days 30, 100, 180, and 360 after hematopoietic cell transplantation (HCT), and multiparameter flow cytometry was performed in a blinded fashion. Reconstitution of CD3+ and CD4+ T cells was delayed up to 6 months post-HCT in the ATLG arm, whereas absolute regulatory T cell (Treg) (CD4+25+127-) numbers were lower only in the first 100 days. Analysis of the CD4+ Treg and conventional T cells (Tconv) (CD4+25–127+) compartments showed a profound absence of naive Tregs and Tconv in the first 100 days post-HCT, with very slow recovery for 1 year. B cell and natural killer cell recovery were similar in each arm. Higher absolute counts of CD3+, CD4+, CD8+ T, Tregs, and Tconv were associated with improved overall survival, progression-free survival, and nonrelapse mortality but not moderate/severe cGVHD. Although ATLG delays CD3+ and CD4+ T cell recovery post-transplant, it has a relative Treg sparing effect after the early post-HCT period, with possible implications for protection from cGVHD. ATLG severely compromises the generation of naive CD4+ cells (Treg and Tconv), potentially affecting the diversity of the TCR repertoire and T cell responses against malignancy and infection. [ABSTRACT FROM AUTHOR]
- Published
- 2018
- Full Text
- View/download PDF
7. Propensity Score Analysis of Conditioning Intensity in Peripheral Blood Haploidentical Hematopoietic Cell Transplantation.
- Author
-
Huselton, Eric, Slade, Michael, Trinkaus, Kathryn M., DiPersio, John F., Westervelt, Peter, and Romee, Rizwan
- Subjects
- *
HEMATOPOIETIC stem cell transplantation , *T cells , *CYCLOPHOSPHAMIDE , *PROGRESSION-free survival , *GRAFT versus host disease , *PROPENSITY score matching , *BONE marrow transplantation - Abstract
Highlights • MAC regimens for haplo-HCT with PTCy were associated with reduced relapse but increased NRM. • There were no differences in OS or DFS between RIC and MAC haplo-HCT patients. • Rates of acute and chronic GVHD were not different between our RIC and MAC patients. Abstract T cell replete HLA-haploidentical hematopoietic cell transplantation (haplo-HCT) with post-transplant cyclophosphamide was originally described using a reduced-intensity conditioning (RIC) regimen. Given that myeloablative conditioning (MAC) is more effective at preventing disease relapse, we compared outcomes of patients receiving MAC and RIC regimens. We evaluated overall survival (OS), disease-free survival (DFS), relapse, nonrelapse mortality (NRM), and graft-versus-host disease (GVHD) of 148 patients that underwent haplo-HCT with either MAC (n = 61) or RIC (n = 87). Propensity score adjustment (PSA) was used to balance baseline characteristics between groups and more effectively compare outcomes based on conditioning intensity. After the PSA analysis, relapse was significantly decreased with MAC (hazard ratio [HR],.47; 95% confidence interval [CI],.31 to.70), but was associated with higher NRM (HR, 1.74; 95% CI, 1.13 to 2.67). OS and DFS were not significantly different between groups (HRs for MAC versus RIC were.87 [95% CI,.64 to 1.18] and.90 [95% CI,.68 to 1.18] for OS and DFS, respectively). Rates of acute and chronic GVHD were not significantly different between groups. This analysis suggests that both MAC and RIC regimens are effective in haplo-HCT and that MAC regimens may result in less relapse in selected patients. These results need to be verified in a larger registry study. [ABSTRACT FROM AUTHOR]
- Published
- 2018
- Full Text
- View/download PDF
8. Fresh or Cryopreserved CD34+-Selected Mobilized Peripheral Blood Stem and Progenitor Cells for the Treatment of Poor Graft Function after Allogeneic Hematopoietic Cell Transplantation.
- Author
-
Ghobadi, Armin, Fiala, Mark A., Ramsingh, Giridharan, Gao, Feng, Abboud, Camille N., Stockerl-Goldstein, Keith, Uy, Geoffrey L., Grossman, Brenda J., Westervelt, Peter, and DiPersio, John F.
- Subjects
- *
CD34 antigen , *GRAFT versus host disease , *HEMATOPOIETIC stem cell transplantation , *PROGENITOR cells , *CANCER chemotherapy , *THERAPEUTICS - Abstract
CD34 + -selected stem cell boost (SCB) without conditioning has recently been utilized for poor graft function (PGF) after allogeneic hematopoietic stem cell transplantation with promising results. Unfortunately, many patients have been unable to receive the boost infusion as their donors were unwilling or unable to undergo an additional stem cell collection. Therefore, we conducted this study utilizing either fresh or cryopreserved peripheral blood stem cell products to create CD34 + -selected boost infusions for the treatment of PGF. Additionally, to explore relationship of CD34 + dose and response, we included a cohort of donors mobilized with plerixafor in addition to the standard granulocyte colony–stimulating factor (G-CSF). Twenty-six patients with PGF were included in this study. Seventeen donor-recipient pairs were enrolled onto the prospective study; an additional 9 patients treated off protocol were reviewed retrospectively. Three different donor products were used for CD34 + selection: (1) fresh mobilized product using G-CSF only, (2) fresh mobilized products using G-CSF and plerixafor, and (3) cryopreserved cells mobilized with G-CSF. CD34 + cell selection was performed using a CliniMACS. The infusion was not preceded by administration of any chemotherapy or conditioning regimen. The primary objective was hematologic response rate and secondary objectives included CD34 + yields, incidence and severity of acute and chronic graft-versus-host disease (GVHD), overall survival (OS), and relapse-free survival (RFS). The median post-selection CD34 + counts per kilogram of recipient weight were 3.1 × 10 6 , 10.9 × 10 6 , and 1 × 10 6 for G-CSF only, G-CSF plus plerixafor, and cryopreserved products, respectively. The median CD34 + yields (defined as the number of CD34 + cells after selection/CD34 + cells before CD34 + selection) were 69%, 66%, and 28% for G-CSF only, G-CSF plus plerixafor, and cryopreserved products, respectively. After SCB, 16 of the 26 recipients (62%) had a complete response, including 5 of 8 (63%) who received cryopreserved products. Five had a partial response (19%), resulting in an overall response rate of 81%. One-year RFS and OS were 50% and 65%, respectively. There was no treatment-related toxicity reported other than GVHD: 6 (23%) developed acute GVHD (2 grade I and 4 grade II) and 8 (31%) developed chronic GVHD (2 limited and 6 extensive). Cryopreserved products are viable alternatives to create SCB for the treatment of PGF. When collecting fresh products is an option, the addition of plerixafor increases CD34 + yield over G-CSF alone; however, it is currently unclear if the CD34 + cell dose impacts the efficacy of the SCB. [ABSTRACT FROM AUTHOR]
- Published
- 2017
- Full Text
- View/download PDF
9. Mobilization of allogeneic peripheral blood stem cell donors with intravenous plerixafor mobilizes a unique graft.
- Author
-
Schroeder, Mark A., Rettig, Michael P., Lopez, Sandra, Christ, Stephanie, Fiala, Mark, Eades, William, Mir, Fazia A., Jin Shao, McFarland, Kyle, Trinkaus, Kathryn, Shannon, William, Deych, Elena, Jinsheng Yu, Vij, Ravi, Stockerl-Goldstein, Keith, Cashen, Amanda F., Uy, Geoffrey L., Abboud, Camille N., Westervelt, Peter, and DiPersio, John F.
- Subjects
- *
HEMATOPOIETIC stem cell transplantation , *IMMUNOLOGICAL adjuvants , *CD34 antigen , *CYTOMEGALOVIRUS diseases , *VIREMIA , *HEMAPHERESIS , *GRAFT versus host disease , *THERAPEUTICS - Abstract
A single subcutaneous (SC) injection of plerixafor results in rapid mobilization of hematopoietic progenitors, but fails to mobilize 33% of normal allogeneic sibling donors in 1 apheresis. We hypothesized that changing the route of administration of plerixafor fromSCto IV may overcome the low stem cell yields and allow collection in 1 day.Aphase 1 trial followed by a phase 2 efficacy trial was conducted in allogeneic sibling donors. The optimal dose of IV plerixafor was determined to be 0.32 mg/kg. The primary outcome of reducing the failure to collect ≥ 2x106 CD34+/kg recipient weight in 1 apheresis collection to ≤10% was not reached. The failure rate was 34%. Studies evaluating the stem cell phenotype and gene expression revealed a novel plasmacytoid dendritic cell precursor preferentially mobilized by plerixafor with high interferon-β producing ability. The observed cytomegalovirus (CMV) viremia rate for patients at risk was low (15%), as were the rates of acute grade 2-4 graft-versus-host disease (GVHD) (21%). Day 100 treatment related mortality was low (3%). In conclusion, plerixafor results in rapid stem cell mobilization regardless of route of administration and resulted in novel cellular composition of the graft and favorable recipient outcomes. [ABSTRACT FROM AUTHOR]
- Published
- 2017
- Full Text
- View/download PDF
10. Phase I study of azacitidine following donor lymphocyte infusion for relapsed acute myeloid leukemia post allogeneic stem cell transplantation.
- Author
-
Ghobadi, Armin, Choi, Jaebok, Fiala, Mark A., Fletcher, Theresa, Liu, Jingxia, Eissenberg, Linda G., Abboud, Camille, Cashen, Amanda, Vij, Ravi, Schroeder, Mark A., Pusic, Iskra, Stockerl-Goldstein, Keith, Jacoby, Meagan, Uy, Geoffrey, DiPersio, John, and Westervelt, Peter
- Subjects
- *
ACUTE myeloid leukemia treatment , *AZACITIDINE , *STEM cell transplantation , *LYMPHOCYTES , *CANCER relapse , *GRAFT versus host disease , *THERAPEUTICS - Abstract
Donor lymphocyte infusion (DLI) without prophylactic immunosuppression has been used for relapsed AML after allogeneic stem cell transplant (allo-SCT). However DLI is associated with an increased incidence of acute Graft vs. Host Disease (aGVHD). In mice, administration of azacitidine (AzaC) on days 4, 6, 8, and 10 post DLI increases regulatory T cell (Treg) numbers and prevents GVHD without hindering Graft vs. Leukemia (GVL). Based on these findings, we conducted a phase 1 study of AzaC post DLI for AML relapse post allo-SCT. AzaC was administered on days 4, 6, 8 and 10 post-DLI. Dose escalation was done using a 3 + 3 design with three AzaC dose levels: 30 mg/m 2 (level −1), 45 mg/m 2 (level 1) and 75 mg/m 2 (level 2). Three patients were treated in the 45 mg/m 2 dose level and 5 patients were treated in the 75 mg/m 2 dose level; no DLTs or grade 3–5 treatment related toxicities were observed. After a median follow-up of 5.2 months, no patients developed grade III–IV aGVHD and no patients died of aGVHD. Six out of 8 patients in the treatment group responded to treatment including two cytogenetic complete remissions, one hematologic complete remission, and three complete remissions with incomplete count recovery. In conclusion, administration of AzaC early post DLI is well tolerated and can potentially prevent GVHD after DLI. Further studies are required to evaluate the effect of azacitidine early post DLI on GVHD and GVL. [ABSTRACT FROM AUTHOR]
- Published
- 2016
- Full Text
- View/download PDF
11. Pre-Conditioning Minus Nadir Serum Albumin in the First Two Weeks after Myeloablative Allogeneic Hematopoietic Cell Transplantation Predicts Subsequent Severe Acute Graft-Versus-Host-Disease.
- Author
-
Rashidi, Armin, DiPersio, John F., Westervelt, Peter, Abboud, Camille, Cashen, Amanda, Pusic, Iskra, Schroeder, Mark A., and Romee, Rizwan
- Subjects
- *
SERUM albumin , *MYELOSUPPRESSION , *HEMATOPOIETIC stem cells , *GRAFT versus host disease , *CLINICAL trials - Published
- 2016
- Full Text
- View/download PDF
12. Chemotherapy versus Hypomethylating Agents for the Treatment of Relapsed Acute Myeloid Leukemia and Myelodysplastic Syndrome after Allogeneic Stem Cell Transplant.
- Author
-
Motabi, Ibraheem H., Ghobadi, Armin, Liu, Jingxia, Schroeder, Mark, Abboud, Camille N., Cashen, Amanda F., Stockler-Goldstein, Keith E., Uy, Geoffrey L., Vij, Ravi, Westervelt, Peter, and DiPersio, John F.
- Subjects
- *
CANCER chemotherapy , *ACUTE myeloid leukemia , *MYELODYSPLASTIC syndromes , *GRAFT versus host disease , *STEM cell transplantation - Abstract
Allogeneic stem cell transplantation (allo-SCT) is a potentially curative treatment for high-risk acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS). For patients with relapsed disease after transplantation, intensive chemotherapy followed by donor lymphocyte infusion (DLI) or a second allo-SCT may result in a durable response in some patients. High-intensity chemotherapy and less aggressive therapy with hypomethylating agents (HAs) with and without DLI are often used for relapse after allo-SCT. Here we compared the treatment outcomes of intensive chemotherapy with that of HAs in relapsed AML and MDS after allo-SCT. Patients who had received a second SCT within 90 days of the relapse date were excluded. The primary endpoints were overall response rate (ORR) and overall survival (OS). Secondary endpoints were complete remission (CR) rate and progression-free survival (PFS). One hundred patients were included: 73 patients received chemotherapy and 27 patients received an HA. Fifty-six percent of patients in the chemotherapy group and 33% of patients in the HA group received at least 1 DLI after treatment. Treatment with chemotherapy resulted in a higher ORR (51% versus 19%, P = .004) and a higher CR rate (40% versus 7%, P = .002). The median OS (6 versus 3.9 months, P = .01) and PFS (4.9 versus 3.8 months, P = .02) were longer in the chemotherapy group. Similar benefit of chemotherapy over HAs was maintained in all treatment outcomes after controlling for the use of DLI. The use of chemotherapy followed by DLI offered the greatest benefit (ORR, 68%; CR, 59%, 1-year OS, 44%; and median OS, 9.8 months). In conclusion, in our hands, with limited numbers, the use of more conventional salvage chemotherapy, with DLI when possible, for the treatment of relapsed AML and MDS after allo-SCT is associated with better outcomes than nonchemotherapy (HA) options. [ABSTRACT FROM AUTHOR]
- Published
- 2016
- Full Text
- View/download PDF
13. Phase 3 clinical trial of steroids/mycophenolate mofetil vs steroids/placebo as therapy for acute GVHD: BMT CTN 0802.
- Author
-
Bolaños-Meade, Javier, Logan, Brent R., Alousi, Amin M., Antin, Joseph H., Barowski, Kate, Carter, Shelly L., Goldstein, Steven C., Hexner, Elizabeth O., Horowitz, Mary M., Lee, Stephanie J., Levine, John E., MacMillan, Margaret L., Martin, Paul J., Mendizabal, Adam M., Nakamura, Ryotaro, Pasquini, Marcelo C., Weisdorf, Daniel J., Westervelt, Peter, and Ho, Vincent T.
- Subjects
- *
STEROIDS , *CLINICAL trials , *MYCOPHENOLIC acid , *GRAFT versus host disease , *ADRENOCORTICAL hormones , *BONE marrow transplant complications - Abstract
Corticosteroids are the accepted primary therapy for acute graft-versus-host disease (GVHD), but durable responses are seen in only about half of the patients. Blood and Marrow Transplant Clinical Trials Network (BMT CTN) 0802, a phase 3 multicenter randomized double-blinded trial, was designed to test whether mycophenolate mofetil (MMF) plus corticosteroids was superior to corticosteroids alone as initial therapy for acute GVHD. Patients with newly diagnosed acute GVHD were eligible if they required systemic therapy. Patients were randomized to receive prednisone with either MMF or placebo. The primary end point was acute or chronic GVHD-free survival at day 56 after initiation of therapy. A futility rule for GVHD-free survival at day 56 was met at a planned interim analysis after 235 patients (of 372) were enrolled: 116 MMF, 119 placebo. Baseline characteristics were well balanced between treatment groups including grade and organ distribution of GVHD. GVHD-free survival at day 56, cumulative incidence of chronic GVHD at 12 months, overall survival, Epstein-Barr virus reactivation, severe, life-threatening infections, relapse at 12 months, and quality of life were similar. The addition of MMF to corticosteroids as initial therapy for acute GVHD does not improve GVHD-free survival compared with corticosteroids alone. [ABSTRACT FROM AUTHOR]
- Published
- 2014
- Full Text
- View/download PDF
14. A Phase II Multicenter Study of Visilizumab, Humanized Anti-CD3 Antibody, to Treat Steroid-Refractory Acute Graft-versus-Host Disease
- Author
-
Carpenter, Paul A., Lowder, James, Johnston, Laura, Frangoul, Haydar, Khoury, Hanna, Parker, Pablo, Jerome, Keith R., McCune, Jeannine S., Storer, Barry, Martin, Paul, Appelbaum, Frederick, Abonour, Rafat, Westervelt, Peter, and Anasetti, Claudio
- Subjects
- *
GRAFT versus host disease , *MONOCLONAL antibodies , *NUCLEIC acids , *CELL proliferation - Abstract
Abstract: Results of a previous phase I study suggested that a single 3 mg/m2 dose of the humanized non-FcR-binding anti-CD3 monoclonal antibody visilizumab (Nuvion) was well tolerated and had efficacy for the treatment of steroid-refractory acute graft-versus-host disease (GVHD). We now report results of a multicenter phase II study in which visilizumab was given to 44 participants with steroid-refractory acute GVHD. Eighty-two percent of the participants had visceral involvement, and 86% had overall grade III or IV acute GVHD at study entry. The respective complete and overall response rates were 14% and 32% at 42 days. Plasma Epstein-Barr virus DNA increased to more than 1000 copies per milliliter in 19 subjects. Seventeen received rituximab, and no fatal lymphoproliferative disorders were observed. Survival at 180 days was 32% (95% confidence interval, 18%-46%). The administration of visilizumab as used in this study seems to be sufficiently safe and effective to warrant further assessment for treatment or prevention of GVHD. [Copyright &y& Elsevier]
- Published
- 2005
- Full Text
- View/download PDF
15. Ruxolitinib for Steroid-Refractory Acute Graft-Versus-Host Diseas.
- Author
-
Toama, Wael, Fiala, Mark A, Pusic, Iskra, Westervelt, Peter, DiPersio, John F., and Schroeder, Mark A.
- Subjects
- *
JANUS kinases , *PROTEIN-tyrosine kinase inhibitors , *STEROID drugs , *GRAFT versus host disease , *HEMATOPOIETIC stem cell transplantation , *DRUG dosage - Abstract
Background Acute graft-versus-host-disease (aGVHD) is one of the leading causes of non-relapse morbidity and mortality following allogeneic hematopoietic cell transplant (allo-HCT). Ruxolitinib (RUX) may be a viable option for patients with steroid-refractory (SR)-aGVHD but limited data currently exists. Methods We performed retrospective chart review to identify patients treated with RUX for S-R-aGVHD 2015-2016 at our center. Primary aGVHD and overlap syndrome were included. Patients who received ≥14 days of RUX were considered evaluable for response assessment. A complete response (CR) was defined as the absence of any symptoms related to aGVHD. A partial response was defined as the improvement of at least one stage in the severity of aGVHD in one organ without deterioration in any other organ. Responses must have maintained for ≥21 days. Results Thirty-six patients were included in the analysis. None were treated on prospective trials of RUX. Demographics are described in Table 1. The median time from allo-HCT to start of RUX was 83 days (range 34-741). The median time from steroid initiation to RUX imitation was 16.5 days (range 2-280) and the median number of prior therapies for S-R-aGVHD was 2 (range 0-5). The majority of patients (72%) were initiated on 5mg BID RUX; 25% were initiated on 10mg BID; 1 patient was initiated on 5mg daily. The median duration of RUX treatment was 21.5 days (range 1-560); 67% received at least 14 days of treatment and were evaluable for response. The overall response rate was 58% with 25% obtaining a CR. RUX was well tolerated; hematologic toxicity was generally mild and not dose limiting and there were no cases of treatment-related mortality. The majority of patients discontinued due to treatment failure or clinical deterioration. Four patients discontinued for toxicity and six for issues in obtaining RUX. Overall, the estimated median overall survival (OS) was 4.9 months (95% CI 2.7-7.0). Of those who were evaluable for response, the median OS was 7.4 months (95% CI UTQ-15.9) for responders compared to 0.9 months (95% CI 0.7-1.1) for non-responders (p < 0.001). The rate of relapse of primary disease was 8%; one patient relapsed while on RUX and two within 6 months following discontinuation. Conclusion In this population of high-risk, S-R-aGVHD, RUX is well tolerated and the ORR is 58% (95% CI 38%-78%) in patients receiving ≥14 days of treatment. [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF
16. 68 - Donor-Lymphocyte Infusion Following Haploidentical Hematopoietic Cell Transplantation with Peripheral Blood Stem Cell Grafts and PTCy.
- Author
-
Goldsmith, Scott R., Slade, Michael, DiPersio, John F., Westervelt, Peter, Uy, Geoffrey L., Abboud, Camille, Vij, Ravi, Schroeder, Mark A., Fehniger, Todd, and Romee, Rizwan
- Subjects
- *
GRAFT versus host disease , *HEMATOPOIETIC stem cell transplantation , *LYMPHOCYTES , *INFUSION therapy , *CYCLOPHOSPHAMIDE , *THERAPEUTICS - Published
- 2017
- Full Text
- View/download PDF
17. Transplant Outcomes in Older Patients Are Comparable to Outcomes in Younger Patients after Hopkin's Non-Myeloablative Flu Cy TBI + PT-Cy Regimen.
- Author
-
Keller, Jesse, DiPersio, John F., Uy, Geoffrey L., Westervelt, Peter, Abboud, Camille, Bhamidipati, Pavan Kumar, Vij, Ravi, Cashen, Amanda, Trinkaus, Kathryn, and Romee, Rizwan
- Subjects
- *
HEMATOLOGIC malignancies , *GRAFT versus host disease , *CYCLOPHOSPHAMIDE , *HEMATOPOIETIC stem cell transplantation , *FLUDARABINE , *TOTAL body irradiation , *HEALTH outcome assessment - Published
- 2015
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.